Genmab Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jan G.J. de Winkel

Geschäftsführender

kr.44.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	20.8%
Amtszeit als Geschäftsführer	14yrs
Eigentum des Geschäftsführers	0.9%
Durchschnittliche Amtszeit des Managements	7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.3yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Jan G.J. de Winkel im Vergleich zu den Einnahmen von Genmab verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	kr.5b
Dec 31 2023	kr.44m	kr.9m	kr.4b
Sep 30 2023	n/a	n/a	kr.4b
Jun 30 2023	n/a	n/a	kr.5b
Mar 31 2023	n/a	n/a	kr.5b
Dec 31 2022	kr.42m	kr.9m	kr.5b
Sep 30 2022	n/a	n/a	kr.6b
Jun 30 2022	n/a	n/a	kr.4b
Mar 31 2022	n/a	n/a	kr.2b
Dec 31 2021	kr.38m	kr.8m	kr.3b
Sep 30 2021	n/a	n/a	kr.3b
Jun 30 2021	n/a	n/a	kr.3b
Mar 31 2021	n/a	n/a	kr.6b
Dec 31 2020	kr.37m	kr.7m	kr.5b
Sep 30 2020	n/a	n/a	kr.6b
Jun 30 2020	n/a	n/a	kr.6b
Mar 31 2020	n/a	n/a	kr.2b
Dec 31 2019	kr.35m	kr.7m	kr.2b
Sep 30 2019	n/a	n/a	kr.2b
Jun 30 2019	n/a	n/a	kr.1b
Mar 31 2019	n/a	n/a	kr.1b
Dec 31 2018	kr.28m	kr.7m	kr.1b
Sep 30 2018	n/a	n/a	kr.1b
Jun 30 2018	n/a	n/a	kr.1b
Mar 31 2018	n/a	n/a	kr.1b
Dec 31 2017	kr.27m	kr.7m	kr.1b

Vergütung im Vergleich zum Markt: Jan G.J.Die Gesamtvergütung ($USD6.38M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt German ($USD5.00M).

Entschädigung vs. Einkommen: Jan G.J.Die Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Jan G.J. de Winkel (63 yo)

14yrs

Amtszeit

kr.44,300,000

Vergütung

Dr. Jan G.J. van de Winkel, Ph.D. is Independent Director of HOOKIPA Pharma Inc. from 2023 and serves as Chairman of the Board since 2024. Dr. Winkel served as a Member of Advisory board at Thuja Capital M...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jan G.J. de Winkel	Co-Founder	14yrs	kr.44.30m	0.95% DKK 145.4m
Anthony Pagano	Executive VP & CFO	4.3yrs	kr.19.60m	0.011% DKK 1.7m
Anthony Mancini	Executive VP & COO	4.3yrs	kr.21.80m	0.0045% DKK 690.5k
Birgitte Stephensen	Executive VP & Chief Legal Officer	14.4yrs	kr.10.10m	keine Daten
Christopher Cozic	Executive VP & Chief People Officer	6.6yrs	kr.13.20m	keine Daten
Martine van Vugt	Executive VP & Chief Strategy Officer	10.4yrs	kr.8.90m	keine Daten
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	no data	kr.800.00k	0.00060% DKK 92.1k
Judith Klimovsky	Executive VP & Chief Development Officer	7.3yrs	kr.21.70m	0.014% DKK 2.1m
Tahamtan Ahmadi	Executive VP	3.3yrs	kr.19.80m	0.0048% DKK 739.6k
Mijke Zachariasse	Senior Director	no data	kr.1.10m	0.00082% DKK 125.8k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	no data	kr.800.00k	0.00013% DKK 19.9k
Andrew Carlsen	Senior Director	no data	keine Daten	keine Daten

7.0yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: GE9Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (7.3 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director	2.4yrs	kr.800.00k	0.00060% DKK 92.1k
Mijke Zachariasse	Senior Director	5.3yrs	kr.1.10m	0.00082% DKK 125.8k
Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director	2.4yrs	kr.800.00k	0.00013% DKK 19.9k
Anders Pedersen	Non-Independent Director	20.6yrs	kr.1.70m	0.011% DKK 1.7m
Elizabeth O'Farrell	Independent Director	2.3yrs	kr.1.90m	keine Daten
Deirdre Connelly	Independent Chairman of the Board	7.3yrs	kr.2.80m	0.0090% DKK 1.4m
Rolf Hoffmann	Independent Director	7.3yrs	kr.1.50m	0.0053% DKK 807.1k
Pernille Erenbjerg	Independent Deputy Chairman	9.4yrs	kr.2.10m	0.0076% DKK 1.2m
Paolo Paoletti	Independent Director	9.4yrs	kr.1.50m	0.0033% DKK 501.7k

7.3yrs

Durchschnittliche Betriebszugehörigkeit

59yo

Durchschnittliches Alter

Erfahrener Vorstand: GE9Die Vorstandsmitglieder gelten als erfahren (7.3 Jahre durchschnittliche Amtszeit).

Genmab Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold €2.9m worth of stock

Genmab A/S, Annual General Meeting, Mar 13, 2024

Co-Founder recently sold €7.8m worth of stock

Independent Chairman of the Board recently bought €107k worth of stock

Insufficient new directors

Recent updates

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Executive VP & CFO recently sold €2.9m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Full year 2023 earnings released: EPS: kr.66.64 (vs kr.84.45 in FY 2022)

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

New minor risk - Profit margin trend

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 17%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022)

Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022)

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold €7.8m worth of stock

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought €107k worth of stock

Full year 2022 earnings released: EPS: kr.84.45 (vs kr.46.00 in FY 2021)

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Co-Founder recently sold €7.7m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Second quarter 2022 earnings released: EPS: kr.28.87 (vs kr.4.68 in 2Q 2021)

Genmab A/S Revises Earnings Guidance for the Year 2022

Investor sentiment improved over the past week

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

First quarter 2022 earnings released: EPS: kr.7.10 (vs kr.16.76 in 1Q 2021)

Genmab A/S Revises Earnings Guidance for 2022

Investor sentiment deteriorated over the past week

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter